(3S,4R,5S,6S)-3-[(2S,3R,4S,5S,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxane-2,4,5-triol

Term ID

CHEBI:150510

Synonyms

alpha-D-galacto-hexopyranosyl-(1->3)-beta-D-galacto-hexopyranosyl-(1->2)-6-deoxy-L-galacto-hexopyranose
Gal(a1-3)Gal(b1-2)Fuc
WURCS=2.0/3,3,2/[a1221m-1x_1-5][a2112h-1b_1-5][a2112h-1a_1-5]/1-2-3/a2-b1_b3-c1

Definition

References

GlyGen:G36220TC
GlyTouCan:G36220TC

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (3S,4R,5S,6S)-3-[(2S,3R,4S,5S,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxane-2,4,5-triol

Phenotype where environments contain (3S,4R,5S,6S)-3-[(2S,3R,4S,5S,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxane-2,4,5-triol

Phenotype modified by environments containing (3S,4R,5S,6S)-3-[(2S,3R,4S,5S,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxane-2,4,5-triol

Phenotype affecting (3S,4R,5S,6S)-3-[(2S,3R,4S,5S,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxane-2,4,5-triol

Human Disease Model